Most cited papers from AbbVie (United States)

AbbVie (United States)

What are the most cited papers from AbbVie (United States)?

The most cited paper from AbbVie (United States) is "FinnGen provides genetic insights from a well-phenotyped isolated population" (Mitja Kurki et al., 2023), with 4,362 citations. Next come "The repertoire of mutational signatures in human cancer" (3,854) and "Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association" (3,719).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 589 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	FinnGen provides genetic insights from a well-phenotyped isolated population Mitja Kurki et al. · Nature Open access169 authors	18 Jan 2023	4,362
2	The repertoire of mutational signatures in human cancer Ludmil B. Alexandrov et al. · Nature Open access1,384 authors	5 Feb 2020	3,854
3	Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association Tiffany M. Powell‐Wiley, Paul Poirier, Lora E. Burke et al. · Circulation Open access	22 Apr 2021	3,719
4	Pan-cancer analysis of whole genomes Lauri A. Aaltonen et al. · Nature Open access1,324 authors	5 Feb 2020	3,360
5	ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets Andrew James Souers et al. · Nature Medicine	6 Jan 2013	3,089
6	Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia Courtney Denton Dinardo et al. · New England Journal of Medicine Open access	12 Aug 2020	2,918
7	New insights into the genetic etiology of Alzheimer’s disease and related dementias Céline Bellenguez et al. · Nature Genetics Open access1,266 authors	Apr 2022	2,608
8	Importance of Assessing Cardiorespiratory Fitness in Clinical Practice: A Case for Fitness as a Clinical Vital Sign: A Scientific Statement From the American Heart Association Robert R. Ross, Steven N. Blair, Ross A Arena et al. · Circulation Open access	21 Nov 2016	2,506
9	Microglia states and nomenclature: A field at its crossroads Rosa Chiara Paolicelli et al. · Neuron Open access	Nov 2022	2,047
10	Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia Andrew Warwick Roberts, Matthew Steven Davids, John M. Pagel et al. · New England Journal of Medicine Open access	6 Dec 2015	1,929
11	Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia Courtney Denton Dinardo, Keith William Pratz, Vinod A. Pullarkat et al. · Blood Open access	26 Oct 2018	1,886
12	Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma Sagar Lonial et al. · New England Journal of Medicine Open access	2 Jun 2015	1,340
13	The evolutionary history of 2,658 cancers Moritz Gerstung et al. · Nature Open access1,441 authors	5 Feb 2020	1,149
14	Strategies for delivering therapeutics across the blood–brain barrier Georg C. Terstappen, Axel H. Meyer, Robert D. Bell et al. · Nature Reviews Drug Discovery Review	Mar 2021	1,139
15	Mapping the human genetic architecture of COVID-19 COVID-19 Host Genetics Initiative et al. · Nature Open access3,896 authors	8 Jul 2021	1,130
16	A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the Sequencing Quality Control Consortium Zhenqiang Su et al. · Nature Biotechnology Open access161 authors	21 Aug 2014	1,092
17	Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia Marina Y Konopleva et al. · Cancer Discovery Open access	12 Aug 2016	1,079
18	Modular Multilevel Converters for HVDC Applications: Review on Converter Cells and Functionalities Alireza Nami, Jiaqi Liang, Frans Dijkhuizen et al. · IEEE Transactions on Power Electronics	2 Jun 2014	1,044
19	p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells Robert J. Ihry, Kathleen A. Worringer, Max R. Salick et al. · Nature Medicine	8 Jun 2018	1,041
20	Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease Dick de Zeeuw, Tadao Akizawa, Paul Audhya et al. · New England Journal of Medicine Open access	9 Nov 2013	1,021
21	An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013–2023) Christopher M. Marshall, John G. Federice, Chloe N. Bell et al. · Journal of Medicinal Chemistry	12 Jul 2024	1,016
22	The Major Risk Factors for Alzheimer’s Disease: Age, Sex, and Genes Modulate the Microglia Response to Aβ Plaques Carlo Sala Frigerio, Leen Wolfs, Nicola Fattorelli et al. · Cell Reports Open access	Apr 2019	1,008
23	Patterns of somatic structural variation in human cancer genomes Yilong Li et al. · Nature Open access1,411 authors	5 Feb 2020	1,005
24	Healthful and Unhealthful Plant-Based Diets and the Risk of Coronary Heart Disease in U.S. Adults Ambika Satija, Shilpa N Bhupathiraju, Donna L. Spiegelman et al. · Journal of the American College of Cardiology Open access	Jul 2017	998
25	Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer Robert Louis Coleman et al. · New England Journal of Medicine Open access	28 Sep 2019	944
26	Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia John Francis Seymour, Thomas J. Kipps, Barbara F. Eichhorst et al. · New England Journal of Medicine Open access	21 Mar 2018	934
27	Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial Jean‐Frédéric Colombel et al. · The Lancet	30 Oct 2017	931
28	From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors Avi Ashkenazi, Wayne J. Fairbrother, Joel D. Leverson et al. · Nature Reviews Drug Discovery Review	17 Feb 2017	926
29	Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin Jordan J. Feld, Kris V. Kowdley, Eoin P. G. Coakley et al. · New England Journal of Medicine Open access	11 Apr 2014	910
30	Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours Loren M. Lasko et al. · Nature Open access	26 Sep 2017	895
31	ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis Fred F Poordad, Christophe Hézode, Roger N. Trinh et al. · New England Journal of Medicine Open access	12 Apr 2014	877
32	Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions Kirsten Fischer et al. · New England Journal of Medicine	4 Jun 2019	875
33	The promise and peril of chemical probes C.H. Arrowsmith et al. · Nature Chemical Biology Open access	21 Jul 2015	864
34	Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study Stephan Stilgenbauer et al. · The Lancet Oncology Open access	10 May 2016	809
35	Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa Alexa B. Kimball et al. · New England Journal of Medicine	3 Aug 2016	804
36	Practical guide to SHAP analysis: Explaining supervised machine learning model predictions in drug development Ana Victoria Ponce Bobadilla, Vanessa Schmitt, Corinna S. Maier et al. · Clinical and Translational Science Open access	28 Oct 2024	803
37	Collagen-producing lung cell atlas identifies multiple subsets with distinct localization and relevance to fibrosis Tatsuya Tsukui, Kai-Hui Sun, Joseph B. Wetter et al. · Nature Communications Open access	21 Apr 2020	798
38	Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing Isidro Cortés-Ciriano et al. · Nature Genetics Open access1,407 authors	5 Feb 2020	793
39	Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial Sibylle Loibl, Joyce O’Shaughnessy, Michael Untch et al. · The Lancet Oncology	28 Feb 2018	781
40	Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial Andrew H. Wei et al. · Blood Open access	27 Mar 2020	774
41	Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia Rongqing Aaron Pan et al. · Cancer Discovery Open access	17 Dec 2013	751
42	The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics Eric H. Karran, Bart De Strooper · Nature Reviews Drug Discovery ReviewOpen access	17 Feb 2022	743
43	Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study Courtney Denton Dinardo, Keith William Pratz, Anthony G. Letai et al. · The Lancet Oncology	12 Jan 2018	730
44	Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study Andrew H. Wei, Stephen Anthony Strickland, Jing-Zhou Hou et al. · Journal of Clinical Oncology Open access	20 Mar 2019	714
45	Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study C. Warren Olanow, Karl D. Kieburtz, Per Odin et al. · The Lancet Neurology Open access	19 Dec 2013	711
46	MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression Mark Magdi Awad, Geoffrey R. Oxnard, David Michael Jackman et al. · Journal of Clinical Oncology Open access	5 Jan 2016	706
47	Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval Emily A. King, J. Wade Davis, Jacob F. Degner · PLoS Genetics Open access	12 Dec 2019	705
48	ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV Péter Ferenci et al. · New England Journal of Medicine Open access	4 May 2014	697
49	Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials Kenneth B. Gordon, Bruce E Strober, Mark Lebwohl et al. · The Lancet	Aug 2018	681
50	Adalimumab in Patients with Active Noninfectious Uveitis Glenn J. Jaffe, Andrew D. Dick, Antoine Pierre Brézin et al. · New England Journal of Medicine Open access	7 Sep 2016	680

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.